"Can I take Ozempic after breast cancer?"
It is becoming an increasingly common question in survivorship clinics.
Often, patients are using "Ozempic" as shorthand for a broader group of medications that includes semaglutide and other glucagon-like peptide-1 receptor agonists (GLP-1 RAs), as well as the dual GIP/GLP-1 receptor agonist tirzepatide. Their questions are understandable. Weight gain is common during and after breast cancer treatment, particularly with chemotherapy, corticosteroids, treatment-induced menopause, and endocrine therapy. At the same time, GLP-1–based therapies have transformed the management of obesity and type 2 diabetes.[1]
But for patients with a history of breast cancer, the question is rarely just, "Will I lose weight?"
What they often want to know is: Is it safe? Could it affect my cancer? Will it interact with my endocrine therapy? And could losing weight reduce my risk of recurrence?
Our answers need to reflect both what we know and, equally importantly, what we do not.
Why Metabolic Health Matters After Breast Cancer
Obesity is not simply a number on the scale. Adipose tissue is metabolically active, and obesity is associated with insulin resistance, inflammation, altered adipokine signaling, and increased estrogen production through aromatase activity. These pathways are biologically relevant to breast cancer, particularly postmenopausal estrogen receptor–positive disease.[1]
Clinically, obesity at diagnosis has also been associated with poorer breast cancer outcomes. A meta-analysis of more than 200,000 patients with early-stage breast cancer found higher breast cancer-specific and overall mortality among patients with obesity.[2]
That does not mean weight loss automatically improves cancer outcomes. This distinction is essential.
Improving metabolic health, glycemic control, cardiovascular risk, and quality of life is valuable in its own right. But we do not yet have prospective evidence showing that GLP-1 RA–associated weight loss reduces breast cancer recurrence or improves breast cancer-specific survival.[1]
When counseling patients, those two ideas should not be conflated.
Do These Medications Work in Breast Cancer Survivors?
Yes, but perhaps not to the same degree seen in the landmark obesity trials.
Breast cancer-specific data remain largely retrospective. In one cohort, GLP-1 RA use was associated with approximately 5% weight loss at one year.[3] In a large retrospective series of breast cancer survivors treated with semaglutide or tirzepatide, median weight loss was 3.1% at six months and 2.6% at 12 months.[1]
Interestingly, concurrent endocrine therapy may matter. Patients receiving aromatase inhibitors or tamoxifen appear to experience less weight loss with GLP-1–based therapies than populations without breast cancer. Another study similarly found less weight loss among breast cancer survivors receiving aromatase inhibitors compared with women without breast cancer receiving anti-obesity medications.[4]
So when a patient says, "My friend lost 15% of her body weight on semaglutide. Why haven't I?" we should recognize that treatment-related metabolic changes may alter response.
We need prospective studies to understand this better.
Are GLP-1 Drugs Safe After Breast Cancer?
So far, no unique breast cancer-specific toxicity has emerged.[1]
That is reassuring, but it does not mean these medications require no additional consideration in cancer survivors.
The usual gastrointestinal toxicities still matter: nausea, vomiting, diarrhea, constipation, and early satiety. In a patient already experiencing poor oral intake, treatment-related nausea, frailty, or cachexia, appetite suppression may be particularly problematic.
Timing also matters. For a patient who has completed active treatment and has obesity or diabetes, the clinical decision may be relatively straightforward. During chemotherapy, around breast reconstruction, or in patients with substantial treatment-related toxicity, it is more complicated.
There are currently no known clinically significant drug-drug interactions between GLP-1 RAs and the major classes of breast cancer therapies. However, these medications delay gastric emptying, and specific pharmacokinetic studies evaluating their effects on oral breast cancer therapies are lacking.[1]
During active treatment, individualized decision-making remains appropriate rather than assuming these drugs should routinely be continued or routinely stopped.
We Need to Talk About Muscle, Not Just Weight
This may be one of the most important conversations we are not having enough.
Weight loss is not synonymous with fat loss.
Studies using DXA and MRI suggest that approximately 25%-45% of weight lost with semaglutide and tirzepatide may be lean body mass.[5] This does not necessarily represent pathologic muscle wasting, and reductions in lean mass have not consistently translated into impaired strength or function. But cancer survivors may already be vulnerable to sarcopenia because of treatment, aging, inactivity, and inadequate nutrition.[1]
That means our endpoint cannot simply be a lower BMI.
When prescribing GLP-1–based therapies to breast cancer survivors, we should also be thinking about resistance exercise, adequate nutrition and protein intake, physical function, and, in higher-risk patients, assessment of muscle strength or body composition.
The goal should be better metabolic health while preserving function and skeletal muscle, not weight loss at any cost.
Could There Be Benefits Beyond Weight Loss?
Possibly, and this is where the field becomes particularly interesting.
GLP-1 RAs have well-established cardiovascular benefits outside oncology. In SELECT, semaglutide reduced cardiovascular events by 20% among individuals with overweight or obesity and established cardiovascular disease without diabetes.[6] Emerging observational oncology data also raise the possibility of benefit in cancer therapy-related cardiac dysfunction, although these findings require prospective confirmation.[1]
Preliminary data also suggest potential associations with reduced breast cancer-related lymphedema. These observations are intriguing, but they remain hypothesis-generating rather than a reason to prescribe GLP-1 RAs specifically to prevent or treat lymphedema.
The same caution applies to cancer outcomes.
Metabolic improvement is biologically compelling. It is not yet evidence of reduced recurrence.
So What Should We Tell Patients?
For a breast cancer survivor with an established indication for obesity or diabetes treatment, a GLP-1–based therapy can be a reasonable option. A history of breast cancer, by itself, is not currently evidence of a contraindication.[1,7]
But our conversation should extend beyond prescribing the medication.
We should ask where the patient is in the cancer treatment continuum, assess nutritional and functional status, monitor gastrointestinal toxicity, protect skeletal muscle through resistance exercise and adequate nutrition, and coordinate with oncology when treatment is ongoing.
Most importantly, we should be precise about expectations.
We can tell patients that these medications can improve weight and metabolic health and have important cardiovascular benefits. We can tell them that the breast cancer-specific safety data available so far are generally reassuring.
What we cannot yet tell them is that Ozempic will prevent their breast cancer from coming back.
That is the question prospective trials need to answer.
References
1. Hundal J, Linz M, Anikreddy S, et al. Glucagon-Like Peptide-1 Receptor Agonists in Breast Cancer: Metabolic, Clinical, and Survivorship Implications. JCO Oncol Pract. Published July 1, 2026. doi:10.1200/OP-26-00061.
2. Chan DSM, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer: systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25:1901-1914.
3. Shen S, Liu B, Fanti C, et al. GLP-1 receptor agonist use and weight change in patients with breast cancer. Oncology. 2025;39:294-296.
4. Fansa S, Ghusn W, Tama E, et al. Efficacy of antiobesity medications among breast cancer survivors taking aromatase inhibitors. Breast Cancer Res Treat. 2024;208:553-563.
5. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(suppl 4):16-27.
6. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221-2232.
7. Parsons K, Montalvo M, Fischbach N, et al. The impact and safety of GLP-1 agents and breast cancer. Cancer Med. 2025;14:e70932.
